Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.86 USD
+0.09 (11.56%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $0.83 -0.03 (-3.38%) 5:18 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.86 USD
+0.09 (11.56%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $0.83 -0.03 (-3.38%) 5:18 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Zacks News
Abaxis (ABAX) Product Portfolio Strong, Competition Rife
by Zacks Equity Research
On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
by Zacks Equity Research
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.
Walgreens (WBA) Tops Q3 Earnings, Scraps Rite-Aid Deal
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.33 in third-quarter fiscal 2017, up 12.7% year over year.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)
by Zacks Equity Research
Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.
Walgreens Boots-LabCorp Tie Up for Patient Service Centers
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA), a major pharmacy-led, health and wellbeing enterprise, recently announced collaboration with leading diagnostic service provider LabCorp (LH).
IDEXX Well-Poised on Strong Fundamentals, Global Growth
by Zacks Equity Research
On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
Quest Diagnostics to Buy Outreach Lab Service in Cape Cod
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.
Hologic (HOLX) Product Pipeline Strong, Competition Rife
by Zacks Equity Research
On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.
NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?
by Zacks Equity Research
On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.
Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes
by Zacks Equity Research
Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.
Penumbra (PEN) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.
3 Reasons Why Accelerate Diagnostics (AXDX) is a Great Momentum Stock
by Zacks Equity Research
Solid price performance both in short and long term makes Accelerate Diagnostics (AXDX) a Great Momentum Stock
ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
by Zacks Equity Research
Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.
Quest Diagnostics Enhances Blueprint for Athletes Service
by Zacks Equity Research
Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.
Why Investors Should Buy Align Technology (ALGN) Right Now
by Zacks Equity Research
Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.
Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.
Here's Why Henry Schein is Worth Adding to Your Portfolio
by Zacks Equity Research
Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.
Why Investors Should Buy Edwards Lifesciences (EW) Right Now
by Zacks Equity Research
Leading CA-based medical equipment major Edwards Lifesciences Corporation (EW) is currently on a healthy growth trajectory.
Why Quest Diagnostics (DGX) is a Suitable Pick for Investors
by Zacks Equity Research
Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.
Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Lantheus Holdings, Inc. (LNTH) has rallied 28.2% over the last three months, ahead of the S&P 500's 4.3% gain.
Baxter (BAX) Scales 52-Week High: What's Behind the Rally
by Zacks Equity Research
Baxter International Inc. (BAX) scaled a new 52-week high of $60.47 on Jun 21, closing a bit lower at $60.05.